SE0104334D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0104334D0
SE0104334D0 SE0104334A SE0104334A SE0104334D0 SE 0104334 D0 SE0104334 D0 SE 0104334D0 SE 0104334 A SE0104334 A SE 0104334A SE 0104334 A SE0104334 A SE 0104334A SE 0104334 D0 SE0104334 D0 SE 0104334D0
Authority
SE
Sweden
Prior art keywords
therapeutic agents
dyslipidemias
enantiomer
prodrugs
solvates
Prior art date
Application number
SE0104334A
Other languages
English (en)
Swedish (sv)
Inventor
Lanna Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104334A priority Critical patent/SE0104334D0/xx
Publication of SE0104334D0 publication Critical patent/SE0104334D0/xx
Priority to CA002470491A priority patent/CA2470491A1/en
Priority to CA002469302A priority patent/CA2469302A1/en
Priority to MXPA04006004A priority patent/MXPA04006004A/es
Priority to PT02804964T priority patent/PT1458673E/pt
Priority to HU0402133A priority patent/HUP0402133A3/hu
Priority to RU2004116918/04A priority patent/RU2300517C2/ru
Priority to KR10-2004-7009517A priority patent/KR20040074094A/ko
Priority to AU2002366315A priority patent/AU2002366315A1/en
Priority to EP02804964A priority patent/EP1458673B1/en
Priority to AU2002352427A priority patent/AU2002352427A1/en
Priority to JP2003552710A priority patent/JP3820249B2/ja
Priority to BR0214986-9A priority patent/BR0214986A/pt
Priority to IL16233002A priority patent/IL162330A0/xx
Priority to US10/499,261 priority patent/US7514471B2/en
Priority to JP2003552709A priority patent/JP3784804B2/ja
Priority to TW091136519A priority patent/TWI255807B/zh
Priority to NZ533276A priority patent/NZ533276A/en
Priority to CNA028281551A priority patent/CN1620423A/zh
Priority to MXPA04006003A priority patent/MXPA04006003A/es
Priority to US10/499,378 priority patent/US7256307B2/en
Priority to SI200230424T priority patent/SI1458673T1/sl
Priority to ES02804964T priority patent/ES2271381T3/es
Priority to UA20040604246A priority patent/UA77460C2/uk
Priority to SI200230570T priority patent/SI1458672T1/sl
Priority to RU2004116917/04A priority patent/RU2303031C2/ru
Priority to ES02788145T priority patent/ES2286310T3/es
Priority to KR10-2004-7009501A priority patent/KR20040074092A/ko
Priority to CNB028281233A priority patent/CN1293044C/zh
Priority to DK02804964T priority patent/DK1458673T3/da
Priority to DK02788145T priority patent/DK1458672T3/da
Priority to PT02788145T priority patent/PT1458672E/pt
Priority to IL16233102A priority patent/IL162331A0/xx
Priority to AT02788145T priority patent/ATE363466T1/de
Priority to PCT/GB2002/005744 priority patent/WO2003051822A1/en
Priority to PL02370672A priority patent/PL370672A1/xx
Priority to UA20040604245A priority patent/UA77987C2/uk
Priority to NZ533274A priority patent/NZ533274A/en
Priority to PCT/GB2002/005738 priority patent/WO2003051821A1/en
Priority to HU0402022A priority patent/HUP0402022A3/hu
Priority to CNB2006100071731A priority patent/CN100406427C/zh
Priority to PL02370673A priority patent/PL370673A1/xx
Priority to BR0214988-5A priority patent/BR0214988A/pt
Priority to EP02788145A priority patent/EP1458672B1/en
Priority to TW091136518A priority patent/TWI253444B/zh
Priority to MYPI20024740A priority patent/MY132565A/en
Priority to AT02804964T priority patent/ATE338743T1/de
Priority to DE60220441T priority patent/DE60220441T2/de
Priority to DE60214594T priority patent/DE60214594T2/de
Priority to ARP020105004A priority patent/AR038047A1/es
Priority to ARP020105002A priority patent/AR038045A1/es
Priority to IL162330A priority patent/IL162330A/en
Priority to ZA200404657A priority patent/ZA200404657B/en
Priority to ZA200404658A priority patent/ZA200404658B/en
Priority to IS7309A priority patent/IS7309A/is
Priority to IS7313A priority patent/IS7313A/is
Priority to NO20043023A priority patent/NO20043023L/no
Priority to NO20043164A priority patent/NO20043164L/no
Priority to US11/026,806 priority patent/US7488844B2/en
Priority to HK05100831A priority patent/HK1068604A1/xx
Priority to HK05101304A priority patent/HK1068870A1/xx
Priority to JP2005235794A priority patent/JP2005336209A/ja
Priority to JP2006123399A priority patent/JP2006298924A/ja
Priority to CY20061101743T priority patent/CY1106276T1/el
Priority to CY20071101028T priority patent/CY1106784T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0104334A 2001-12-19 2001-12-19 Therapeutic agents SE0104334D0 (sv)

Priority Applications (65)

Application Number Priority Date Filing Date Title
SE0104334A SE0104334D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
CA002470491A CA2470491A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
CA002469302A CA2469302A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
MXPA04006004A MXPA04006004A (es) 2001-12-19 2002-12-18 Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
PT02804964T PT1458673E (pt) 2001-12-19 2002-12-18 Derivados substituídos do ácido fenilpropiónico como agonistas do receptor alfa activado por proliferador de peroxissoma (ppar) humano
HU0402133A HUP0402133A3 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar), process for their preparation and pharmaceutical compositions containing them
RU2004116918/04A RU2300517C2 (ru) 2001-12-19 2002-12-18 ПРОИЗВОДНЫЕ ЗАМЕЩЕННОЙ ФЕНИЛПРОПИОНОВОЙ КИСЛОТЫ КАК АГОНИСТЫ АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ АЛЬФА-РЕЦЕПТОРА ЧЕЛОВЕКА (PPARα), СПОСОБ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ИХ ПРИМЕНЕНИЕ И СПОСОБЫ ЛЕЧЕНИЯ ДИСЛИПИДЕМИИ И ДИАБЕТА 2 ТИПА
KR10-2004-7009517A KR20040074094A (ko) 2001-12-19 2002-12-18 인간 과산화소체 증식인자 활성화 수용체알파(ｐｐａｒ)에 대한 작용제로서의 치환된페닐프로피온산 유도체
AU2002366315A AU2002366315A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator activated receptor alpha (PPAR)
EP02804964A EP1458673B1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
AU2002352427A AU2002352427A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
JP2003552710A JP3820249B2 (ja) 2001-12-19 2002-12-18 ヒトペルオキソーム増殖因子活性化受容体α（ＰＰＡＲ）のアゴニストである置換フェニルプロピオン酸誘導体
BR0214986-9A BR0214986A (pt) 2001-12-19 2002-12-18 S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
IL16233002A IL162330A0 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
US10/499,261 US7514471B2 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α (PPAR)
JP2003552709A JP3784804B2 (ja) 2001-12-19 2002-12-18 ヒトのペルオキシソーム増殖因子活性化受容体α（ＰＰＡＲ）に対するアゴニストとしての置換フェニルプロピオン酸誘導体
TW091136519A TWI255807B (en) 2001-12-19 2002-12-18 Therapeutic agents
NZ533276A NZ533276A (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
CNA028281551A CN1620423A (zh) 2001-12-19 2002-12-18 作为人过氧化物酶体增殖物激活受体α(PPAR)激动剂的取代苯基丙酸衍生物
MXPA04006003A MXPA04006003A (es) 2001-12-19 2002-12-18 Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano.
US10/499,378 US7256307B2 (en) 2001-12-19 2002-12-18 Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α(PPAR)
SI200230424T SI1458673T1 (sl) 2001-12-19 2002-12-18 Substituirani derivati fenilpropionske kisline kot agonisti za humani peroksizomsko proliferatorsko aktivirani receptor ALFA (PPAR)
ES02804964T ES2271381T3 (es) 2001-12-19 2002-12-18 Derivados de acido fenilpropionico sustituido como agonistas del receptor alfa activado por proliferador de peroxisoma (ppar) humano.
UA20040604246A UA77460C2 (en) 2001-12-19 2002-12-18 Substituted derivatives of phenylpropionic acid as agonists of alpha-receptor activated by peroxysome proliferator, method of preparation, pharmaceutical composition, intermediate (variants)
SI200230570T SI1458672T1 (sl) 2001-12-19 2002-12-18 Substituirani derivati fenilpropionske kisline kot agonisti humanega alfa-receptorja, aktivnega s peroksisomskim proliferatorjem (PPAR)
RU2004116917/04A RU2303031C2 (ru) 2001-12-19 2002-12-18 ПРОИЗВОДНЫЕ ЗАМЕЩЕННОЙ ФЕНИЛПРОПИОНОВОЙ КИСЛОТЫ КАК АГОНИСТЫ АКТИВИРУЕМОГО ПРОЛИФЕРАТОРОМ ПЕРОКСИСОМ АЛЬФА- РЕЦЕПТОРА ЧЕЛОВЕКА (PRARα) СПОСОБ И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ИХ ПРИМЕНЕНИЕ И СПОСОБЫ ЛЕЧЕНИЯ ДИСЛИПИДЕМИИ ДИАБЕТА 2 ТИПА
ES02788145T ES2286310T3 (es) 2001-12-19 2002-12-18 Derivados del acido fenilpropionico sustituido como agonistas del receptor alfa activado por proliferador de peroxisoma (ppar) humano.
KR10-2004-7009501A KR20040074092A (ko) 2001-12-19 2002-12-18 인간 과산화소체 증식인자 활성화 수용체알파(ｐｐａｒ)에 대한 작용제로서의 치환된페닐프로피온산 유도체
CNB028281233A CN1293044C (zh) 2001-12-19 2002-12-18 作为人过氧化物酶体增殖物激活受体α(PPAR)激动剂的取代苯基丙酸衍生物
DK02804964T DK1458673T3 (da) 2001-12-19 2002-12-18 Substituerede phenylpropionsyrederivater som agonister for human peroxisomproliferatoraktiveret receptor alfa (PRAR)
DK02788145T DK1458672T3 (da) 2001-12-19 2002-12-18 Substituerede phenylpropionsyrederivater som antagonister af human peroxisomproliferatoraktiveret receptor alfa (PPAR)
PT02788145T PT1458672E (pt) 2001-12-19 2002-12-18 Derivados do ácido fenilpropiónico substituído como agonistas para o receptor alfa activado por proliferador de perixissoma humano ( ppar )
IL16233102A IL162331A0 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
AT02788145T ATE363466T1 (de) 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
PCT/GB2002/005744 WO2003051822A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
PL02370672A PL370672A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
UA20040604245A UA77987C2 (en) 2001-12-19 2002-12-18 Substituted derivatives of phenylpropionic acid as agonists of peroxisome proliferators activated alpha receptor, method for synthesis, pharmaceutical composition, intermediate (variants)
NZ533274A NZ533274A (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR)
PCT/GB2002/005738 WO2003051821A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
HU0402022A HUP0402022A3 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) and pharmaceutical compositions containing them
CNB2006100071731A CN100406427C (zh) 2001-12-19 2002-12-18 作为人过氧化物酶体增殖物激活受体α(PPAR)激动剂的取代苯基丙酸衍生物
PL02370673A PL370673A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
BR0214988-5A BR0214988A (pt) 2001-12-19 2002-12-18 S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
EP02788145A EP1458672B1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar)
TW091136518A TWI253444B (en) 2001-12-19 2002-12-18 Therapeutic agents
MYPI20024740A MY132565A (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
AT02804964T ATE338743T1 (de) 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar)
DE60220441T DE60220441T2 (de) 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
DE60214594T DE60214594T2 (de) 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar)
ARP020105004A AR038047A1 (es) 2001-12-19 2002-12-19 Agentes terapeuticos
ARP020105002A AR038045A1 (es) 2001-12-19 2002-12-19 Agentes terapeuticos
IL162330A IL162330A (en) 2001-12-19 2004-06-03 Substituted phenylpropionic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for the treatment of lipid disorders (dyslipidemias), whether or not associated with insulin resistance
ZA200404657A ZA200404657B (en) 2001-12-19 2004-06-11 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (PPAR).
ZA200404658A ZA200404658B (en) 2001-12-19 2004-06-11 Substituted phenylpropionic acid derivatives as aginist to human peroxisome proliferator-activated receptor alpha (PPAR).
IS7309A IS7309A (is) 2001-12-19 2004-06-14 Útskiptar fenýlprópíónsýruafleiður sem gerandefnioxunarkorns fjölgunarvirkjaðs alfaviðtaka í manni(ppar)
IS7313A IS7313A (is) 2001-12-19 2004-06-15 Útskiptar fenýlprópíónsýruafleiður sem gerandefnioxunarkorns fjölgunarvirkjaðs alfaviðtaka í manni(ppar)
NO20043023A NO20043023L (no) 2001-12-19 2004-07-15 Substituerte fenylpropionsyre-derivater som agonister mot human proliferator-aktivert reseptor alfa (PPAR)
NO20043164A NO20043164L (no) 2001-12-19 2004-07-16 Substituerte fenylpropionsyre-derivater som agonister mot human peroksisom-proliferator-aktivert reseptor alfa (PPAR)
US11/026,806 US7488844B2 (en) 2001-12-19 2004-12-30 Therapeutic agents
HK05100831A HK1068604A1 (en) 2001-12-19 2005-02-01 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
HK05101304A HK1068870A1 (en) 2001-12-19 2005-02-16 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
JP2005235794A JP2005336209A (ja) 2001-12-19 2005-08-16 ヒトのペルオキシソーム増殖因子活性化受容体α（ＰＰＡＲ）に対するアゴニストとしての置換フェニルプロピオン酸誘導体
JP2006123399A JP2006298924A (ja) 2001-12-19 2006-04-27 置換フェニルプロピオン酸誘導体を含む医薬組成物
CY20061101743T CY1106276T1 (el) 2001-12-19 2006-12-05 Παραγωγα υποκατεστημενου φαινυλπροπιονικου οξεος ως ανταγωνιστες σε υποδοχεις αλφα που ενepγοποιουνται απο παραγοντες που επαγουν τον πολλαπλασιασμο των ανθρωπινων υπepοξεισωματων (ppar)
CY20071101028T CY1106784T1 (el) 2001-12-19 2007-08-01 Υποκατεστημενα παραγωγα φαινυλ προπιονικου οξεος ως συναγωνιστες του ανθρωπινου υπεροξυσωματικου πολλαπλασιαστη - ενεργοποιημενου υποδοχεα αλφα (ppar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104334A SE0104334D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0104334D0 true SE0104334D0 (sv) 2001-12-19

Family

ID=20286433

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104334A SE0104334D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Country Status (31)

Country Link
US (2) US7256307B2 (ru)
EP (2) EP1458673B1 (ru)
JP (4) JP3784804B2 (ru)
KR (2) KR20040074094A (ru)
CN (3) CN1293044C (ru)
AR (2) AR038045A1 (ru)
AT (2) ATE338743T1 (ru)
AU (2) AU2002352427A1 (ru)
BR (2) BR0214988A (ru)
CA (2) CA2470491A1 (ru)
CY (2) CY1106276T1 (ru)
DE (2) DE60220441T2 (ru)
DK (2) DK1458672T3 (ru)
ES (2) ES2271381T3 (ru)
HK (2) HK1068604A1 (ru)
HU (2) HUP0402022A3 (ru)
IL (3) IL162331A0 (ru)
IS (2) IS7309A (ru)
MX (2) MXPA04006004A (ru)
MY (1) MY132565A (ru)
NO (2) NO20043023L (ru)
NZ (2) NZ533274A (ru)
PL (2) PL370673A1 (ru)
PT (2) PT1458673E (ru)
RU (2) RU2303031C2 (ru)
SE (1) SE0104334D0 (ru)
SI (2) SI1458672T1 (ru)
TW (2) TWI255807B (ru)
UA (2) UA77987C2 (ru)
WO (2) WO2003051822A1 (ru)
ZA (2) ZA200404658B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) * 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
WO2004000789A1 (en) * 2002-06-19 2003-12-31 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
RU2004137094A (ru) 2002-06-20 2005-08-10 Астразенека Аб (Se) Орто-замещенные производные бензойной кислоты для лечения инсулинорезистентности
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1644375A2 (en) 2003-07-14 2006-04-12 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
CN1886364A (zh) * 2003-12-15 2006-12-27 伊莱利利公司 选择性过氧化物酶体增殖物激活受体调节剂
RU2391340C2 (ru) * 2004-08-11 2010-06-10 Киорин Фармасьютикал Ко., Лтд. Новое циклическое производное аминобензойной кислоты
SE0403072D0 (sv) * 2004-12-16 2004-12-16 Astrazeneca Ab Pharmaceutically useful salts of carboxylic acid derivates
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
TWI331523B (en) * 2005-12-08 2010-10-11 Nat Health Research Institutes Vinylsulfonate compounds
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101890959B1 (ko) 2010-11-08 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
JO3301B1 (ar) * 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3242666B1 (en) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PT3310760T (pt) 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JOP20200297A1 (ar) 2018-06-20 2020-11-22 Albireo Ab تعديلات بلورية للأوديفيكسيبات
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2023039276A1 (en) * 2021-09-13 2023-03-16 Curtails Llc Use of ibat inhibitors and antimicrobials for the treatment of diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266121C (ru)
BE489216A (ru) 1948-06-05 1900-01-01
US2928840A (en) 1958-11-26 1960-03-15 Us Vitamin Pharm Corp 3-(o-substituted phenyl) oxazolidinediones and process therefor
GB1081471A (en) 1963-09-13 1967-08-31 Stauffer Chemical Co Glycol amide derivatives and use thereof in controlling weed growth
US3244398A (en) 1963-10-28 1966-04-05 Scaramucci Domer Composite seat ball valve
AT307640B (de) 1970-06-18 1973-05-25 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen
BE792364A (fr) 1971-12-06 1973-06-06 Basf Ag Derives de substitution du sulfonylglycolanilide
DE2349256C2 (de) 1973-10-01 1985-08-01 Basf Ag, 6700 Ludwigshafen 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide
DE2828222A1 (de) 1978-06-28 1980-01-10 Bayer Ag Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide
US4735959A (en) 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US5312924A (en) 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5216167A (en) 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
US6410585B1 (en) 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
EP1019364B1 (en) 1997-08-28 2004-06-09 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
CA2309792A1 (en) 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
AU760163B2 (en) 1999-04-06 2003-05-08 Sankyo Company Limited Alpha-substituted carboxylic acid derivatives
AU3670900A (en) * 1999-04-08 2000-11-14 Sankyo Company Limited Substituted fused imidazole derivatives
WO2000061585A2 (en) 1999-04-14 2000-10-19 The University Of British Columbia (Ubc) 1,3-dipolar cycloadditions to polypyrrolic macrocycles
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
BR0010605A (pt) 1999-04-28 2002-02-13 Aventis Pharma Gmbh Derivados ácidos de di-aril como ligantes de receptores ppar
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001261612A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
JPWO2002044130A1 (ja) 2000-11-29 2004-04-02 杏林製薬株式会社 置換カルボン酸誘導体
JPWO2002044127A1 (ja) 2000-11-29 2004-04-02 杏林製薬株式会社 置換カルボン酸誘導体
WO2002064549A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
WO2002083616A1 (fr) 2001-04-10 2002-10-24 Sankyo Company, Limited DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2004000789A1 (en) 2002-06-19 2003-12-31 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
GB0314134D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
HUP0402022A3 (en) 2009-06-29
US20050113362A1 (en) 2005-05-26
JP2006298924A (ja) 2006-11-02
KR20040074094A (ko) 2004-08-21
CN1620422A (zh) 2005-05-25
PL370672A1 (en) 2005-05-30
CN1620423A (zh) 2005-05-25
JP2005526011A (ja) 2005-09-02
CN1896045A (zh) 2007-01-17
MY132565A (en) 2007-10-31
RU2300517C2 (ru) 2007-06-10
PT1458673E (pt) 2006-12-29
JP3820249B2 (ja) 2006-09-13
HUP0402022A2 (hu) 2005-01-28
CA2470491A1 (en) 2003-06-26
US7256307B2 (en) 2007-08-14
TWI253444B (en) 2006-04-21
AU2002366315A1 (en) 2003-06-30
US20050171204A1 (en) 2005-08-04
JP2005526704A (ja) 2005-09-08
CY1106276T1 (el) 2011-10-12
CA2469302A1 (en) 2003-06-26
SI1458673T1 (sl) 2007-02-28
WO2003051821A1 (en) 2003-06-26
ES2271381T3 (es) 2007-04-16
MXPA04006003A (es) 2004-09-27
CY1106784T1 (el) 2012-05-23
JP3784804B2 (ja) 2006-06-14
TW200410918A (en) 2004-07-01
ES2286310T3 (es) 2007-12-01
RU2004116918A (ru) 2005-11-10
WO2003051822A1 (en) 2003-06-26
ZA200404657B (en) 2005-08-29
DE60220441D1 (de) 2007-07-12
EP1458672A1 (en) 2004-09-22
PT1458672E (pt) 2007-07-18
JP2005336209A (ja) 2005-12-08
ZA200404658B (en) 2006-02-22
NZ533276A (en) 2006-04-28
UA77460C2 (en) 2006-12-15
EP1458672B1 (en) 2007-05-30
ATE338743T1 (de) 2006-09-15
BR0214988A (pt) 2004-12-14
RU2303031C2 (ru) 2007-07-20
US7514471B2 (en) 2009-04-07
DE60214594D1 (de) 2006-10-19
IL162330A (en) 2009-06-15
HK1068604A1 (en) 2005-04-29
NO20043164L (no) 2004-07-16
IL162330A0 (en) 2005-11-20
DK1458673T3 (da) 2006-12-11
BR0214986A (pt) 2004-12-14
HK1068870A1 (en) 2005-05-06
NZ533274A (en) 2005-12-23
TW200410925A (en) 2004-07-01
KR20040074092A (ko) 2004-08-21
DK1458672T3 (da) 2007-09-17
IL162331A0 (en) 2005-11-20
NO20043023L (no) 2004-07-15
DE60220441T2 (de) 2008-01-24
UA77987C2 (en) 2007-02-15
CN1293044C (zh) 2007-01-03
IS7313A (is) 2004-06-15
AU2002352427A1 (en) 2003-06-30
AR038047A1 (es) 2004-12-22
MXPA04006004A (es) 2004-09-27
HUP0402133A2 (hu) 2005-02-28
TWI255807B (en) 2006-06-01
EP1458673B1 (en) 2006-09-06
PL370673A1 (en) 2005-05-30
CN100406427C (zh) 2008-07-30
AR038045A1 (es) 2004-12-22
DE60214594T2 (de) 2007-09-13
RU2004116917A (ru) 2005-11-10
ATE363466T1 (de) 2007-06-15
SI1458672T1 (sl) 2007-10-31
IS7309A (is) 2004-06-14
HUP0402133A3 (en) 2010-07-28
EP1458673A1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
SE0104334D0 (sv) Therapeutic agents
TW200508180A (en) Therapeutic agents
TW200503674A (en) Therapeutic agents
SE0202462D0 (sv) Novel use
SE0104340D0 (sv) New compounds
SI1326613T2 (sl) Uporaba substituiranih imidazo/1,2-a/piridin-, -pirimidin - in -pirazin-3-il-aminskih derivatov za pripravo zdravil za inhibiranje NOS
NO20051263L (no) Ny anvendelse av benzotiazolderivater
MY137156A (en) Dual nk1/nk3 derivatives
MY135920A (en) New phenalkyloxy-phenyl derivatives
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
AR036351A1 (es) Isoxazolopiridinonas, el uso de las mismas para la fabricacion de un medicamento, composiciones y combinaciones farmaceuticas
SE0104333D0 (sv) Therapeutic agents
SE0101978D0 (sv) New compounds
SE9900190D0 (sv) New compounds
ES2111086T3 (es) Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos.
PT1082116E (pt) Utilizacao de derivados de 4-piperidinometanol no tratamento de desordens do neurodesenvolvimento
HUP0301548A2 (hu) NMDA receptor ligandok előgyógyszerei, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
TW200502202A (en) Therapeutic agents
SE0201936D0 (sv) Therapeutic agents
NZ510001A (en) 6-sulphamoyl-3-quinolylphosponic acid compounds for treating hyperactivation of neurotransmission paths to excitatory amino acids, alzheimer's disease, huntington's disease, spinal or cerebral traumatism or epilepsy
UY28142A1 (es) Agentes terapéuticos
SG153727A1 (en) Substituted pyridinones as modulators of p38 map kinase